Company profile

Celltrion

068270 · KRX

Public Market Listing

068270KRX

KRX primary exchange listing

Live quotes, historical charts, and market capitalization for Celltrion are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(9 total)
9Total Assets
3Approved
6Phase 3 / Filed
0Phase 1–2 / Early
5Diseases
Quick filter:
Showing 9 of 9 assets
Target & Modality
Aflibercept(Eylea)
Approved
VEGF-A · VEGF-A / VEGF-B / Placental Growth Factor (PlGF)Protein / enzyme therapeutic
Age-Related Macular Degeneration
CT-P47 (tocilizumab)(Avtozma)
Approved
IL-6 receptorMonoclonal antibody
Rheumatoid Arthritis
Vegzelma (bevacizumab-adcd)
Approved
VEGF-AMonoclonal antibody
Non-Small Cell Lung Cancer
CT-P10No recent activity
Phase 3
CD20Monoclonal antibody
Rheumatoid Arthritis
CT-P13
Phase 3
TNF-alphaMonoclonal antibody
Rheumatoid Arthritis
CT-P17No recent activity
Phase 3
TNF-alphaMonoclonal antibody
Rheumatoid Arthritis
CT-P44
Phase 3
CD38Monoclonal antibody
Multiple Myeloma
CT-P51
Phase 3
PD-1Small molecule
Non-Small Cell Lung Cancer
CT-P53
Phase 3
CD20Monoclonal antibody
Multiple Sclerosis

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.